NovoCure Ltd
NVCR- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001645113
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
218
- −6 vs. Q1 2026
- Total value $1.57B
Superinvestors holding NVCR
0
- None of the superinvestors held NVCR at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by NVCR insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Jun 4, 2026 | Leonard Frank XChief Executive Officer | SSaleOrdinary Shares | −34.27K | $17.93 | −$614.51K | 459.52K | −6.9% | SEC |
| Jun 3, 2026 | Jun 2, 2026 | Stafford KristinDirector | SSaleOrdinary Shares | −2.95K | $15.77 | −$46.44K | 11.32K | −20.6% | SEC |
| Jun 3, 2026 | Jun 2, 2026 | Ocean Allyson JDirector | SSaleOrdinary Shares | −2.95K | $15.77 | −$46.44K | 11.32K | −20.6% | SEC |
| Jun 3, 2026 | Jun 2, 2026 | Scannell Timothy JDirector | SSaleOrdinary Shares | −2.95K | $15.77 | −$46.44K | 14.29K | −17.1% | SEC |
| Jun 3, 2026 | Jun 2, 2026 | VERNON W ANTHONYDirector | SSaleOrdinary Shares | −2.95K | $15.77 | −$46.44K | 197.66K | −1.5% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in NVCR at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 17,373,078 | $263.2M | 0.01% | +303,929+1.8% | Added |
| BlackRock, Inc. | 13,413,699 | $203.22M | 0.00% | +219,934+1.7% | Added |
| Soleus Capital Management, L.P. | 9,913,401 | $150.19M | 5.18% | −578,990−5.5% | Reduced |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,272,490 | $95.03M | 0.00% | +20,789+0.3% | Added |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,903,633 | $74.29M | 0.00% | +221,569+4.7% | Added |